Federated Hermes, Inc. Otonomy, Inc. Transaction History

Federated Hermes, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$1.69 - $2.31 $1.58 Million - $2.15 Million	-932,500 Reduced 19.2%	3,923,700 $8.16 Million
Q1 2021 May 13, 2021	BUY	$2.49 - $6.23 $2.3 Million - $5.77 Million	925,551 Added 23.55%	4,856,200 $12.4 Million
Q4 2020 Feb 12, 2021	SELL	$3.48 - $6.47 $417 - $776	-120 Reduced -0.0%	3,930,649 $25.4 Million
Q3 2020 Nov 12, 2020	BUY	$3.16 - $4.36 $12.4 Million - $17.1 Million	3,930,769 New	3,930,769 $15.9 Million
Q3 2018 Nov 13, 2018	SELL	$2.6 - $3.95 $1,346 - $2,046	-518 Closed	0 $0
Q1 2018 May 09, 2018	SELL	$4.05 - $6.1 $4,037 - $6,081	-997 Reduced 65.81%	518 $2,000
Q4 2017 Feb 14, 2018	SELL	$2.8 - $5.55 $2,710 - $5,372	-968 Reduced 38.99%	1,515 $0
Q3 2017 Nov 13, 2017	BUY	$3.2 - $20.8 $7,945 - $51,646	2,483	2,483 $8,000

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.